Precision Medicine Group Joins the Business Coalition for Equality Act
The Equality Act, currently moving through Congress, would make LGBTQ+ discrimination explicitly illegal. Precision Medicine Group believes that this Act is too important to leave its passage to chance. That is why we have joined a group of 446 leading American companies in signing the Business Coalition for the Equality Act. (more…)
On-Demand Webinar: Essential Strategies for Gene Therapy: From Assay Development to CDx Commercialization
Innovators developing gene therapies face a multitude of challenges, from the lab to the FDA. Yet a number of successful strategies are emerging that are mitigating the risks, reducing costs and smoothing out the road to approval. Listen to a panel of gene therapy experts with unique perspectives and real-world experiences share successful approaches in gene therapy development, CDx development and commercialization.
Gene Therapy for Rare Disorders Panel Summary
Recently, Precision ADVANCE’s Anshul Mangal moderated “Considerations for Early-Stage Gene Therapy Start-Ups: From Clinical Development to Manufacturing to Commercialization,” at the Gene Therapy for Rare Disorders virtual conference.
Precision ADVANCE Company Presentation: Meeting on the Med
At the Meeting on the Med 2021 Conference, CEO & Co-Founder of Precision Medicine Group Mark Clein gave an informative presentation highlighting Precision ADVANCE, the cell & gene therapy collective™, and how it aligns with our mission to help bring life-changing therapies to those that need them the most.
On-Demand Webinar: Continuing the Conversation-The Future of Reimbursement for Cell and Gene Therapies
Expanding upon his presentation at the recent World EPA Congress, moderator Richard Macaulay and Precision Value & Health have assembled a unique panel of payers from UK, Germany, and Italy, plus experts within Precision to address how innovative reimbursement strategies for cell and gene therapies (C>s) will evolve.